Cholinergic anti-inflammatory pathway and COVID-19

Danial Mehranfard; Robert Speth

doi:10.34172/bi.2022.23980

Cholinergic anti-inflammatory pathway and COVID-19

Danial Mehranfard
, Robert Speth

Nova Southeastern University

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

The cholinergic anti-inflammatory pathway (CAP) first described by Wang et al, 2003 has contemporary interest arising from the COVID-19 pandemic. While tobacco smoking has been considered an aggravating factor in the severity of COVID-19 infections, it has been suggested by some that the nicotine derived from tobacco could lessen the severity of COVID-19 infections. This spotlight briefly describes the CAP and its potential role as a therapeutic target for the treatment of COVID-19 infections using vagus nerve stimulation or selective alpha7 nicotinic acetylcholine receptor agonists.

Original language	American English
Pages (from-to)	171-174
Number of pages	4
Journal	BioImpacts : BI
Volume	12
Issue number	2
DOIs	https://doi.org/10.34172/bi.2022.23980
State	Published - Jan 1 2022

Bibliographical note

Keywords

Alpha 7 nicotinic acetylcholine receptor
COVID-19
Cholinergic anti-inflammatory pathway
Vagus nerve stimulation

Disciplines

Medicine and Health Sciences
Pharmacy and Pharmaceutical Sciences

Access to Document

10.34172/bi.2022.23980License: Unspecified

Cholinergic anti-inflammatory pathway and COVID-19Final published version, 1.1 MBLicense: Unspecified

https://doi.org/10.34172/bi.2022.23980

Cite this

@article{6e9d6a91f8ec426887c1bf8f7b6a5342,

title = "Cholinergic anti-inflammatory pathway and COVID-19",

abstract = " The cholinergic anti-inflammatory pathway (CAP) first described by Wang et al, 2003 has contemporary interest arising from the COVID-19 pandemic. While tobacco smoking has been considered an aggravating factor in the severity of COVID-19 infections, it has been suggested by some that the nicotine derived from tobacco could lessen the severity of COVID-19 infections. This spotlight briefly describes the CAP and its potential role as a therapeutic target for the treatment of COVID-19 infections using vagus nerve stimulation or selective alpha7 nicotinic acetylcholine receptor agonists.",

keywords = "Alpha 7 nicotinic acetylcholine receptor, COVID-19, Cholinergic anti-inflammatory pathway, Vagus nerve stimulation",

author = "Danial Mehranfard and Robert Speth",

note = "{\textcopyright} 2022 The Author(s).",

year = "2022",

month = jan,

day = "1",

doi = "10.34172/bi.2022.23980",

language = "American English",

volume = "12",

pages = "171--174",

journal = "BioImpacts : BI",

issn = "2228-5660",

publisher = "Tabriz University of Medical Sciences",

number = "2",

}

TY - JOUR

T1 - Cholinergic anti-inflammatory pathway and COVID-19

AU - Mehranfard, Danial

AU - Speth, Robert

PY - 2022/1/1

Y1 - 2022/1/1

N2 - The cholinergic anti-inflammatory pathway (CAP) first described by Wang et al, 2003 has contemporary interest arising from the COVID-19 pandemic. While tobacco smoking has been considered an aggravating factor in the severity of COVID-19 infections, it has been suggested by some that the nicotine derived from tobacco could lessen the severity of COVID-19 infections. This spotlight briefly describes the CAP and its potential role as a therapeutic target for the treatment of COVID-19 infections using vagus nerve stimulation or selective alpha7 nicotinic acetylcholine receptor agonists.

AB - The cholinergic anti-inflammatory pathway (CAP) first described by Wang et al, 2003 has contemporary interest arising from the COVID-19 pandemic. While tobacco smoking has been considered an aggravating factor in the severity of COVID-19 infections, it has been suggested by some that the nicotine derived from tobacco could lessen the severity of COVID-19 infections. This spotlight briefly describes the CAP and its potential role as a therapeutic target for the treatment of COVID-19 infections using vagus nerve stimulation or selective alpha7 nicotinic acetylcholine receptor agonists.

KW - Alpha 7 nicotinic acetylcholine receptor

KW - COVID-19

KW - Cholinergic anti-inflammatory pathway

KW - Vagus nerve stimulation

UR - https://nsuworks.nova.edu/hpd_facarticles/41

U2 - 10.34172/bi.2022.23980

DO - 10.34172/bi.2022.23980

M3 - Article

C2 - 35411295

SN - 2228-5660

VL - 12

SP - 171

EP - 174

JO - BioImpacts : BI

JF - BioImpacts : BI

IS - 2

ER -

Cholinergic anti-inflammatory pathway and COVID-19

Abstract

Bibliographical note

Keywords

Disciplines

Access to Document

Other files and links

Fingerprint

Cite this